The Journal of Pediatrics
Volume 125, Issue 5 , Pages 805-811, November 1994

Serum sickness–like reactions to cefaclor: Role of hepatic metabolism and individual susceptibility☆☆★★

Presented in part at the 94th annual meeting of the American Society for Clinical Pharmacology and Therapeutics, Honolulu, Hawaii, March 24-26, 1993.

Received 25 March 1994; accepted 24 June 1994.

Abstract 

In an effort to explain the increased incidence of serum sickness-like reactions (SSLR) in patients receiving cefaclor, we used an in vitro murine microsomal system as a surrogate for in vivo hepatic drug biotransformation. Lymphocytes from three groups of subjects were exposed to a nonselective mixture of cefaclor metabolites. After an 18-hour incubation of lymphocytes with these metabolites, cells were examined for viability by trypan blue exclusion. The subject groups consisted of patients with a previous history of SSLR after cefaclor therapy (n = 19), patients who experienced adverse reactions to cefaclor suggestive of immediate hypersensitivity (n = 11), and control subjects who had previously tolerated at least two courses of cefaclor therapy without adverse effect (n = 9). Additionally, immediate family members of six subjects with cefaclor-associated SSLR were studied. Lymphocyte killing was 100% greater than baseline (i.e., a non-drug-containing control) in subjects with SSLR compared with those with immediate hypersensitivity reactions (4% cell death above baseline; p <0.001) and nonaffected control subjects (6% cell death above baseline; p <0.001). Family studies were consistent with a pattern of maternal inheritance; five of six mothers who had not received cefaclor had a positive (i.e., ≥35% cell death above baseline) in vitro cytotoxic response. Other studies confirmed the requirement for biotransformation of the parent drug to elicit cell death, demonstrated specificity of the reaction to cefaclor, illustrated a lack of cross-reactivity to cephalexin in subjects with SSLR to cefaclor, and verified the reproducibility of the reaction over time in an affected subject. Our findings indicate that cefaclor-associated SSLR may be a unique adverse drug reaction that requires biotransformation of the parent drug and may result from inherited defects in the metabolism of reactive intermediates. Furthermore, this condition can be retrospectively confirmed with an in vitro lymphocyte-based cytotoxicity assay. (J PEDIATR 1994;125:805-11)

Abbreviations:  DMSO , Dimethyl sulfoxide, SSLR , Serum sickness-like reaction

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. No PDF version available.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 From the Divisions of Pediatric Clinical Pharmacology and of Allergy and Clinical Immunology, Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital Research Institute, Inc., Little Rock

☆☆ Supported in part by a grant-in-aid from Eli Lilly and Company, Indianapolis, Ind.

 Reprint requests: Gregory L. Kearns, BS(Pharm), PharmD, Division of Pediatric Clinical Pharmacology, Department of Pediatrics, Arkansas Children's Hospital, 800 Marshall St., Little Rock, AR 72202.

★★ 0022-3476/94/$3.00 + 0 9/25/58771

PII: S0022-3476(94)70112-1

The Journal of Pediatrics
Volume 125, Issue 5 , Pages 805-811, November 1994